Pirmagrel

Pirmagrel
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Pirmagrel is a pharmaceutical compound that acts as an antiplatelet agent. It is primarily used in the prevention of thrombotic cardiovascular events such as myocardial infarction and stroke. Pirmagrel functions by inhibiting platelet aggregation, which is a crucial step in the formation of blood clots.

Mechanism of Action

Pirmagrel works by selectively inhibiting the enzyme cyclooxygenase (COX), specifically the COX-1 isoform, in platelets. This inhibition prevents the conversion of arachidonic acid to thromboxane A2, a potent vasoconstrictor and promoter of platelet aggregation. By reducing thromboxane A2 levels, Pirmagrel effectively decreases platelet aggregation and thrombus formation.

Pharmacokinetics

Pirmagrel is administered orally and is well absorbed from the gastrointestinal tract. It undergoes hepatic metabolism, primarily through the cytochrome P450 enzyme system, and is excreted mainly via the kidneys. The elimination half-life of Pirmagrel is approximately 4 to 6 hours, allowing for once-daily dosing in most therapeutic regimens.

Clinical Uses

Pirmagrel is indicated for the prevention of:

• Myocardial infarction in patients with a history of coronary artery disease.
• Ischemic stroke in patients with a history of cerebrovascular disease.
• Peripheral arterial disease to reduce the risk of thrombotic events.

Adverse Effects

Common adverse effects of Pirmagrel include:

• Gastrointestinal disturbances such as nausea and dyspepsia.
• Increased risk of bleeding, including gastrointestinal bleeding and hemorrhagic stroke.
• Hypersensitivity reactions, although rare, can occur.

Contraindications

Pirmagrel is contraindicated in patients with:

• Active bleeding disorders.
• Known hypersensitivity to the drug or its components.
• Severe hepatic impairment.

Drug Interactions

Pirmagrel may interact with other medications that affect hemostasis, such as:

• Warfarin and other anticoagulants, increasing the risk of bleeding.
• Nonsteroidal anti-inflammatory drugs (NSAIDs), which may enhance gastrointestinal bleeding risk.

Research and Development

Ongoing research is exploring the potential of Pirmagrel in combination therapies for enhanced antithrombotic effects. Studies are also investigating its role in patients with genetic variations affecting platelet function.

Also see

• Antiplatelet drug
• Thromboxane
• Cyclooxygenase
• Myocardial infarction
• Ischemic stroke

This article is a stub related to pharmacology. You can help WikiMD by expanding it!